| Title | Author(s) | Year | View Count |
 | Coexisting ductal carcinoma in situ independently predicts lower tumor aggressiveness in node-positive luminal breast cancer | Wong, H; Lau, S; Leung, R; Chiu, J; Cheung, P; Wong, TT; Liang, R; Epstein, RJ; Yau, T | 2012 | 63 |
 | Presence of an in situ component is associated with reduced biological aggressiveness of size-matched invasive breast cancer | Wong, H; Lau, S; Yau, T; Cheung, P; Epstein, RJ | 2010 | 133 |
| PPI-delayed diagnosis of gastrinoma: Oncologic victim of pharmacologic success | Wong, H; Yau, T; Chan, P; Ng, IOL; Chan, G; Hui, P; Law, WL; Lo, CM; Hedley, AJ; Epstein, RJ | 2010 | 387 |
| Transient carcinoembryonic antigen elevations during adjuvant chemotherapy for colorectal cancer reflect the burden of residual micrometastatic disease | Yau, T; Wong, H; Chan, P; Chan, T; Mak, J; Epstein, R | 2010 | 118 |
| Visual impairment in myopic patients with breast cancer receiving adjuvant therapy with aromatase inhibitors | Epstein, RJ | 2009 | 94 |
| Management of advanced hepatocellular carcinoma in the era of targeted therapy | Yau, T; Chan, P; Epstein, R; Poon, RTP | 2009 | 86 |
| Complications of traditional Chinese/herbal medicines (TCM)-a guide for perplexed oncologists and other cancer caregivers | Chiu, J; Yau, T; Epstein, RJ | 2009 | 92 |
| Methicillin-resistant commensal staphylococci in healthy dogs as a potential zoonotic reservoir for community-acquired antibiotic resistance | Epstein, CR; Yam, WC; Peiris, JSM; Epstein, RJ | 2009 | 159 |
| The threat that dare not speak its name: Human extinction | Epstein, RJ; Zhao, Y | 2009 | 122 |
| TNM: Therapeutically Not Mandatory | Epstein, RJ | 2009 | 72 |
| The outcomes of elderly patients with hepatocellular carcinoma treated with transarterial chemoembolization | Yau, T; Yao, TJ; Chan, P; Epstein, RJ; Ng, KK; Chok, SH; Cheung, TT; Fan, ST; Poon, RTP | 2009 | 222 |
 | Growth inhibition of human cancer cells by 5-aza-2'-deoxycytidine does not correlate with its effects on INK4a/ARF expression or initial promoter methylation status. | Xiong, J; Epstein, R | 2009 | 116 |
| Predictive value of 18F-FDG PET-CT in primary breast cancer patients receiving neoadjvuant chemotherapy | Tsang, JWH; Yeung, DWC; Chan, ACY; Wong, HN; Leung, LWS; Lo, CSY; Fung, LHK; Epstein, R; Kwong, A | 2009 | 134 |
| Hoarseness during treatment with bevacizumab and other vascular endothelial growth factor signalling inhibitors | Wong, H; Yau, T; Man, CW; Epstein, RJ | 2009 | 102 |
| Loading doses for costly cancer biologicals: Sound pharmacology or unnecessary extravagance? | Epstein, RJ; Cheung, BMY | 2008 | 103 |
| Tumor resensitization to erlotinib following brief substitution of cetuximab | Epstein, RJ; Leung, TW | 2008 | 80 |
| Treatment outcomes in anaplastic thyroid carcinoma: survival improvement in young patients with localized diseases treated by combination surgery and radiotherapy | Yau, T; Lo, CY; Epstein, R; Lam, AK; Wan, KY; Lang, BHH | 2008 | 85 |
| Evolution of systemic therapy of advanced hepatocellular carcinoma | Yau, T; Chan, P; Epstein, R; Poon, RT | 2008 | 114 |
| Bevacizumab-based therapy for advanced small bowel adenocarcinoma | Tsang, H; Yau, T; Khong, PL; Epstein, RJ | 2008 | 75 |
| Treatment outcomes in anaplastic thyroid carcinoma: Survival improvement in young patients with localized disease treated by combination of surgery and radiotherapy | Yau, T; Lo, CY; Epstein, RJ; Lam, AKY; Wan, KY; Lang, BH | 2008 | 134 |
|
